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Effect of tumour necrosis factor and lipid A on functional and structural
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Summary Effects of recombinant tumour necrosis factor (TNF) on functional and structural vascular
volumes in solid murine Meth A tumours were investigated by injection of Hoechst 33342 and staining for the
vascular basement membrane component laminin, respectively. Systemic injection of 3 x 104 U TNF caused an
initial increase in functional volume in the tumour, but a strong decrease from I to 48 h after treatment. Early
effects of intralesional treatment were more moderate. Systemic injection of 104 U TNF or 0.3 or 3 1tg lipid A
caused a fall in functional volume at 4 h, hut a recovery was seen at 24 h. This recovery did not occur after
treatment with a combination of 104 U' TNF and 0.3 ytg lipid A. Structural vascular volume was not markedly
reduced until 24 h after treatment with the high doses of the separate agents and the combination. All effects
appeared generally more prominent in the tumour centre than in the borders. Data suggest that TNF induces
initially an active hyperaemia that rapidly converts to passive hyperaemia. A prolonged disturbance of tumour
blood supply is probably necessary for therapeutic activity. Breakdown of laminin in the vascular basement
membrane may be a cause of loss of vascular integrity.
The ability of endotoxins to induce necrosis of established
solid tumours has been the subject of many studies (Gratia &
Linz, 1931; Shear & Perrault, 1943; Nowotny, 1985). Tumour
necrosis factor (TNF), predominantly produced by mono-
nuclear phagocytes upon injection of endotoxin, is assumed
to be a pivotal mediator of this effect (Carswell et al., 1975),
but an involvement of other endotoxin-induced factors is
indicated by the synergic anti-tumour activity of endotoxin
and TNF (Bloksma & Hofhuis, 1987; Chun & Hofmann,
1987). The synergy also indicates that the agents have a
different mode of action. Such a difference has been found in
the in vitro anti-tumour activity of the agents. Only TNF was
found to display harmful effects to several neoplastic cell
lines (Fransen et al., 1986; Nakano et al., 1986). Observa-
tions, however, that TNF can induce extensive necrosis of
tumours that lack sensitivity to TNF in vitro (Creasey et al.,
1986; Asher et al., 1987; Bloksma & Hofhuis, 1987) suggest
that, at least in these instances, the tumour cells are killed by
an indirect mechanism. Ample data have indicated that the
tumour vasculature is a primary target of the action of TNF
and endotoxin (Gratia & Linz, 1931; Shear & Perrault, 1943;
Kawai et al., 1987). Among other effects, hyperaemia, con-
gestion, thrombus formation and vascular damage have been
observed in tumours within 4 h of treatment with either of
both agents (Kuper et al., 1982; Kawai et al., 1987; Van de
Wiel et al., 1989). In Meth A tumours the central portion
appeared to be most vulnerable to induction of these effects
and subsequent development of extensive tumour necrosis,
which was previously distinguished in haemorrhagic necrosis
near the skin and coagulation necrosis in the core (Kuper et
al., 1982, 1988; Van de Wiel et al., 1989). Moreover, in SAl
tumours functional evidence of an early disturbance of
tumour blood flow upon TNF treatment has been obtained
by using 51Cr-labelled erythrocytes (Havell et al., 1988).
These data together suggest, but do not establish, a rela-
tion between vascular damage, reduced blood flow and
tumour necrosis. We therefore used a recently described
method (Murray et al., 1987) to coincidently estimate both
functional (FV) and structural (SV) vascular volumes in mar-
gins and core of Meth A tumours at various times after
treatment with tumour-necrotising agents inducing different
degrees of necrosis.
Materials and methods
Mice and tumour
Female BALB/c mice from Harlan/CPB (Zeist, The Nether-
lands) were used at an age of 9 weeks when they weighed
about 20 g. The syngeneic Meth A fibrosarcoma (Bloksma et
al., 1982) was maintained in ascites form by serial intra-
peritoneal passage.
Materials
Recombinant human TNF with a specific activity of 1.5 x
IO' U mg-' was kindly provided by Knoll/BASF (Ludwig-
shafen, FRG). Lipid A from the Salmonella typhimurium Re
mutant, that lacks the polysaccharide chain of the endotoxin
molecule, was obtained from Ribi ImmunoChem (Hamilton,
MT, USA). Stock solutions (5 mgml-') of this agent were
made in 0.5% (v/v) triethylamine in saline. Bisbenzimide
Hoechst 33342 (H33342) was bought from Calbiochem (La
Jolla, CA, USA). Agents were dissolved in or further diluted
with pyrogen-free saline immediately before injection.
Rabbit antiserum to human laminin, cross-reacting with
mouse laminin, was provided by EY Laboratories (San
Mateo, CA, USA). Horseradish-peroxidase (HRP)-labelled
swine anti-rabbit and rabbit anti-rat antisera were obtained
from DAKO (Copenhagen, Denmark), and tetra-methyl-
rhodamine isothiocyanate (TRITC)-labelled goat-anti-rabbit
antiserum from Nordic (Tilburg, The Netherlands). Mono-
clonal rat-anti-mouse endothelium (MECA-20) antibodies
(Duijvestijn et al., 1987) were generously given by Dr A.M.
Duijvestijn (Biomedical Centre, Maastricht, The Nether-
lands).
Tumour model
The Meth A tumour model was used as has been described
previously (Bloksma et al., 1982). Briefly, BALB/c mice
received an injection with 3 x 101 viable Meth A tumour cells
into the abdomen. After 9 days, when the mice bore a
tumour with a mean diameter of about 7 mm localised in
both cutis and subcutis (Kuper et al., 1988), indicated
amounts of TNF, lipid A or the combination were injected
intravenously (i.v.) in a volume of 0.3 ml or intralesionally
(i.l.) in a volume of 0.05 ml. In some experiments the
incidence of hyperaemia and necrosis was scored at 4 and
24 h after treatment, respectively. Hyperaemia was assessed
by determining the degree of red discolouration of the
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tumours. Necrosis was assessed by the presence of brown- or
black-stained discolouration of the central portion of the
tumour. The extent of necrosis was expressed by the mean of
largest and perpendicular diameters of the discolouration
relative to the mean diameter of the tumour.
At specific times after injection of the tumour-necrotising
agents H33342 (0.8 mg in 0.3 ml saline per mouse) was
injected i.v. Mice were killed by cervical dislocation 20 s later
and tumours were rapidly excised with surrounding skin
tissue in a way that head-tail orientation could be recognised
later on. They were subsequently frozen in liquid nitrogen
and stored at -70°C.
Determination ofFVand SV
Sagittal frozen sections (6ytm) of the central portion of the
tumours were dried overnight at room temperature and
examined with a fluorescence microscope. H33342 was visual-
ised at excitation and emission wavelengths of 376 nm and
418 nm, respectively. H33342-positive vessel transsections
were counted at four different sites, each representing 0.38
square mm, in the tumour sections. The sites were located as
indicated in Figure 1 and selected by using phase-contrast
microscopy at low magnification. Coordinates of the sites
were noted down. Using an ocular grid of 10 x 10 squares
and a magnification of 160 x arbitrary units of FV were
determined according to the following criteria. The central
region offluorescent halo was considered to outline the vessel
and squares to be counted had to be covered by at least 25%
of this region. Sections were scored blindly.
After determination of FV sections were fixed in acetone
and allowed to air-dry. Then, they were incubated with a
1/80 dilution of anti-laminin antiserum for 60 min, followed
by a 45 min incubation with 1/40 diluted HRP-labelled anti-
rabbit antiserum. Staining was performed using 3-amino-9-
ethylcarbazole with hydrogen peroxide as substrate (Bahn et
al., 1980). Sections were counterstained with haematoxylin,
and subsequently mounted with a solution of gelatin in
water. All procedures were carried out at room temperature.
Instead of the anti-laminin staining we have also applied a
vascular staining with MECA-20 as first antibody and HRP-
labelled anti-rat antibody as second antibody, and instead of
the immunoperoxidase staining TRITC-labelling also has
been used. In all cases arbitrary units of SV were determined
by counting squares with laminin-positive vessels at exactly
the same sites and in the same way as FV.
Data handling andstatistics
FV and SV were determined in three sections per tumour and
used to calculate the mean per tumour site or per tumour.
Figures from similarly treated animals in the same experi-
ment were combined by calculating the mean ± s.e.m. Statis-
tical analysis was performed using a single factor analysis of
variance with a posteriori multiple comparison. P-values
lower than 0.05 were considered as significant.
Results
Determination ofoptimum conditionsfor vascular staining of
Meth A
Functional vessels could be visualised at a high resolution in
tumour sections of mice injected with 0.8 mg H33342 20 s
before sacrifice (Figure 2a). Longer circulation times resulted
in loss of vessel definition, in particular in areas with a high
density of functional vessels. Reduction of the injected dose
of H33342 down to 0.1 mg led to a dose-dependent decrease
in fluorescence intensity of the functional vessels, but did not
affect estimation of FV in the tumour (data not shown).
The endothelium specific MECA-20 monoclonal antibodies
appeared to give a poor staining of the large blood vessels in
the tumour after application of TRITC-labelled as well as
HRP-labelled secondary antibodies. With the anti-laminin
antibodies a good staining of all vessels was obtained in all
instances, but fat cells were also stained as checked by oil-
red-oil staining. Since vessels and fat cells could be differ-
Ventral
Figure 1 Schematic representation of a Meth A sarcoma section
and the sites chosen for determination of FV and SV. Areas with
spontaneous necrosis (E) and induced haemorrhagic necrosis
(M), and surrounding skin (E) are shown.
Figure 2 a, Fluorescent halos of H33342-positive (functional)
vessels in a Meth A tumour ( x 207, bar = 50gm). b, Survey of a
Meth A section of a saline-injected mouse after incubation with
anti-laminin antibodies and HRP-staining. Vascular structures
are visible in the vital tissue but not in the necrotic tissue below
( x 67.5, bar = 100pm). c, Detail of b showing a laminin-positive
vessel (left) and a fat cell (right) ( x 378, bar = 25pm).720 P.A. VAN DE WIEL et al.
entiated with bright-field optics (Figure 2b and c), the
laminin-immunoperoxidase staining was used to determine
SV in the remaining experiments.
Route- and time-dependence ofthe vascular effects ofTNF
A dose of 3 x IO' U TNF, which caused a reproducible high
incidence of cures in previous experiments (Bloksma & Hof-
huis, 1987; Van de Wiel et al., 1989), was injected i.v. or i.l.
into Meth A bearing mice and effects on FV and SV in
tumours were investigated at specific times (Figure 3). As
effects on vascular volumes at the different sites in the
tumour were similar, data from these sites have been com-
bined.
Comparison of FV and SV in control tumours revealed
that less than half of the vessels were functional at each time
measured. I.v. injection of 3 x IO U TNF caused an increase
in FV in the tumour as compared to the controls at 15 and
30 min (Figure 3). At 1 h FV was strongly reduced, and
apparently nullified at 4 h. Recovery of blood flow was not
evident during the period of observation. TNF caused a
reduction of the intensity of the laminin-staining which was
more pronounced at the later times. SV was slightly increased
at 1 h, but no further distinct effects of the treatment on SV
were seen within the first 4 h. At 24 and 48 h, however, TNF
caused a marked reduction of SV.
I.1. injection of TNF did not cause an increase in FV at
15-30 min. From 1 to 4 h of treatment a gradual reduction
of FV was seen, and resumption was not observed in the
remaining period. Effects on intensity of the laminin-staining
and on SV were generally similar to those of i.v. injected
TNF (Figure 3).
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Macroscopic and vascular effects ofTNF, lipid A, and a
combination
Tumour-bearing mice were treated i.v. with one of two doses
of TNF or lipid A or with a combination for macroscopic
determination of hyperaemia and necrosis and assessment of
FV and SV. Macroscopic effects of TNF and lipid A on the
tumours were very consistent with those of previous studies
(Bloksma et al., 1982; Bloksma & Hofhuis, 1987; Van de
Wiel et al., 1989). A dose of 3 x I04 U TNF caused marked
red discolouration of the tumours at 4 h, and dark-stained
necrosis of the central tumour portion at 24 h (Table I). The
effect of 104 U TNF was more moderate. Similarly, a dose-
dependent degree of hyperaemia and necrosis was seen after
treatment with 3 and 0.3tsg lipid A. Macroscopic anti-
tumour effects of a combination of I04 U TNF with 0.3ttg
lipid A were much stronger than effects of the separate
constituents (Table I).
After determination of hyperaemia at 4 h, some of the
mice were injected with H33342 to assess FV and SV. The
remaining mice were similarly treated after determination of
necrosis at 24 h. Effects on vascular volume at sites 1 and 2
(borders) were comparable, and, therefore, the data have
been combined. Injection of 3 x 104 U TNF or 3 sg lipid A
caused a strong and significant reduction of FV at all sites at
4 h (Figure 4). More moderate but still significant effects
were observed after treatment with a lower dose of the agents
or the combination.
By 24 h a resumption of blood flow to almost control
values was seen in tumours from mice treated with 1O' U
TNF as well as 0.3jig lipid A (Figure 4). After injection of
3jig lipid A a recovery of FV was only seen in the tumour
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Figure 3 Route- and time-dependence of effects of 3 x I04 U TNF on functional and structural vascular volume in Meth A.
Symbols represent mean ± s.e.m. of two animals killed at the times indicated, except the controls which represent the mean ± s.e.m.
of five animals injected i.v. or i.l. with saline and killed 0.5, 1, 2, 4 and 24 h after treatment. Arbitrary units (AU) of vascular
volume have been defined in Materials and methods.
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Table I Induction of hyperaemia and necrosis of murine Meth A
sarcoma by TNF, lipid A or a combination
Dose of Incidence of Incidence of Extent of
TNF lipid A hyperaemiaa necrosis' necrosis'
(U) (jg) + + ± + (%)
- - 2/8 - 1/4 - 5±5
104 6/12 5/12 5/6 1/6 49±5
3 x104 2/8 6/8 - 4/4 68 7d
0.3 4/12 1/12 5/6 - 31±7
- 3 4/8 3/8 1/4 3/4 54± 5e
104 0.3 3/12 9/12 1/6 5/6 63±5e
alncidence ofmoderate ( ± ) and marked (+) red discolouration of
tumours was scored at 4 h. bIncidence ofbrown ( ± ) and black-stained
( + ) necrosis of the central portion of the tumour was scored at 24 h.
cExtent ofnecrosis at 24 h wasexpressed as 100 times the ratio ofmean
diameters ofnecrotic area and tumour, respectively. Figures represent
themean±s.e.m. ofall tumourswith and without necrosis. dp<0.05 as
compared to I04 U TNF. eP<0.05 as compared to 0.3 1sg lipid A.
borders, whereas in case of the high dose of TNF alone and
the combination no recovery was seen both in tumour core
and borders.
SV was not affected 4 h after injection of the agents. At
24 h, however, a significant reduction of SV was induced in
the tumour core by the high doses of lipid A and TNF, and
by the combination, whereas in the tumour borders only the
latter two treatments had significant effects on SV (Figure 4).
Discussion
Effects of local and systemic administration of TNF on FV
and SV were compared, because local treatment was pre-
viously found to be far more effective in inducing necrosis
and cures (Van de Wiel et al., 1989). In the present study
differences were also observed with regard to the early effects
on FV. It was increased shortly after i.v. injection of TNF,
but not after local treatment. Four hours after both treat-
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ments, however, FV had been virtually nullified despite overt
macroscopic red discolouration of the tumours. Data to-
gether suggest that TNF induces initially an active hyper-
aemia, especially after i.v. injection, that rapidly converts to
passive hyperaemia.
The route-dependent difference in early action of TNF on
FV may be related to the more marked systemic effects ofi.v.
administered TNF as indicated by the higher toxicity ofTNF
given by this route in comparison with local administration
(Diehl et al., 1988; Van de Wiel et al., 1989). Probably, blood
pressure disturbances and release of vasoamines known to
cause hyperaemia and necrosis of solid tumours (Shear &
Perrault, 1943; Bloksma et al., 1984b) are more pronounced
upon systemic treatment. However, these prompt effects are
apparently not required for curative activity, because local
treatment is more effective in this respect than systemic treat-
ment (Van de Wiel et al., 1989).
The previously observed increase in the number of dilated
vessels in paraffin- or plastic-embedded tumour sections at
4 h of treatment with TNF or endotoxin (Kuper et al., 1982;
Bloksma et al., 1984b; Van de Wiel et al., 1989) was not
evident in laminin-stained frozen sections, because SV was
normal or even slightly reduced at those times. The decrease
in staining intensity may have led to an underestimation of
SV. Stretching of the basement membrane of the dilated
vessels may be implicated. In that case laminin staining
would not be suitable for determination of SV. Another
interesting possibility is that laminin has been degraded by
proteolytic enzymes known to be implicated in the tumor-
icidal action ofendotoxin and TNF (Adams, 1980; Beyaert et
al., 1987). Such a mechanism is not unlikely because of the
reported extreme protease sensitivity of laminin in sarcomas
as compared with other tumours and normal tissues (Leu &
Damjanov, 1988). Since laminin is a major component of the
basement membrane, its degradation may be involved in the
previously observed vascular damage induced by these agents
(Havell et al., 1988; Van de Wiel et al., 1989). This will be
the subject of further investigation.
Comparison of the effects of different doses of TNF and
24 h
[T
*
IL
T
T
T T
J I
|] TI
I UVU ; A I U IJ V.@ Ilg J >
TNF TNF Lipid A Lipid A
10"U TNF +
0.3 ,ug Lipid A
baiinne lu"u Xx -0-U u.3 iLg
TNF TNF Lipid A
3 iLg
Lipid A
104U TNF +
0.3 Ag Lipid A
Figure 4 Effect of TNF, lipid A or a combination on functional and structural vascular volume at different sites in Meth A 4 and
24 h after i.v. administration. Bars represent mean arbitrary units ± s.e.m. (n = 4-6). Asterisks indicate a significant decrease as
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lipid A on FV supports the idea that early effects on FV are
not crucial for tumour destruction, because all treatments
reduced the FV to about the same degree at 4 h (Figure 4),
while induction of tumour necrosis by the agents appeared to
be dose-dependent (Table I; Bloksma & Hofhuis, 1987; Van
de Wiel et al., 1989). At 24 h, however, blood flow had
completely resumed in tumours of mice treated with the
lower doses, but not at all or only partially after treatment
with the high dose of TNF and lipid A, respectively. The
combination caused effects similar to those of the high dose
of TNF. Since reduction of FV and SV at 24 h appeared
correlated to induction of extensive tumour necrosis (Figure
5) and to previously noted high incidences of cures (Bloksma
& Hofhuis, 1987; Van de Wiel et al.,1989), it is very likely
that a prolonged disturbance of the tumour blood supply
favours definite regression. This is in line with data that
mechanically induced occlusion of tumour-supplying vessels
only resulted in local cure when the occlusion was main-
tained for at least 15 h (Denekamp et al., 1983).
The relation between disturbed vascular function and
tumour necrosis is also indicated by the observation that the
vascular effects of the agents were most marked in the central
portion of the tumour (Figure 4), which is known to be the
most susceptible to development of spontaneous necrosis as
well as to induction of necrosis by tumour-necrotising agents
(Kuper et al., 1982, 1988; Kawai et al., 1987; Van de Wiel et
al., 1989). The pre-eminent vulnerability ofthe tumour centre
may be related to a pre-existent poor blood supply (Jain,
1988; Tozer et al., 1990). Apparently, blood flow in this area
is already critical for tumour cells to survive. Hence, a fur-
ther reduction is likely to create conditions that are incom-
patible with cell survival. Other abnormalities in tumours,
like the high interstitial pressure (Denekamp, 1984; Jain,
1988) and the poor homeostatic control by the lack of
smooth musculature and collateral vessels (Denekamp, 1984)
may contribute to the maintenance of blood flow distur-
bance, and explain why tumour tissue is more vulnerable to
induction of necrosis than normal tissues.
The causative mechanisms of the prompt reduction of
tumour blood flow are still not well understood. A possible
role of hypotension and vasoamines has already been men-
tioned. Also induction of increased viscous resistance of the
blood by TNF has been suggested to be involved (Sevick &
Jain, 1989). Occlusion of tumour vessels by formation of
intravascular thrombi is a frequently mentioned cause (Bevi-
lacqua et al., 1986; Kawai et al., 1987; Nawroth et al., 1988).
In Meth A tumours fibrin deposition and occlusive thrombi
has been observed at 30 min and at 2 h after TNF treatment,
respectively (Nawroth et al., 1988). Our observation of a
dramatic fall in blood flow between 30 min and 1 h of treat-
ment is not in disagreement with these data. It is doubtful,
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Figure 5 Relationship between extent of necrosis and functional
and structural vascular volume in Meth A 24 h after i.v. adminis-
tration of the agents or a combination.
however, whether the thrombi are induced by TNF through
local elicitation ofendothelial cell procoagulant activity, since
this activity was only apparent after 3 h of coincubation of
endothelial cells and TNF in vitro (personal communication,
Dr P. Hasselaar, Academical Hospital, Utrecht, The Nether-
lands). Another possibility is that the thrombi are the conse-
quence of stasis of blood flow.
Although agents with a selective action on the tumour
vasculature would be welcome in the treatment of cancer,
clinical application of tumour-necrotising agents is limited up
till now by their severe toxicity. This may be circumvented by
using less toxic combinations ofagents proven to have even a
greater therapeutic activity in the mouse model (Bloksma et
al., 1984a; Bloksma & Hofhuis, 1987). Another strategy is to
combine TNF application with other treatments, such as
hyperthermia, gamma-radiation and chemotherapy (Hara-
naka et al., 1987; Krosnick et al., 1989). Our present findings
may have important implications for such combination
therapies. They suggest that hyperthermia treatment must be
applied shortly after TNF treatment, when tumour blood
flow is at its minimum, and heat-transport is hampered. On
the other hand, the expected induction ofhypoxia in tumours
by TNF and the known low responsiveness of hypoxic cells
to radiation and cytostatic agents (Denekamp, 1984) suggest
that application of radio- and chemotherapy will be most
successful before TNF treatment. Moreover, the TNF-induc-
ed passive hyperaemia in the tumour would thwart the
accessibility of the tumour to chemotherapeutic agents.
These studies were financially supported by a grant of the Dutch
Cancer Society.
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